Ars Pharmaceuticals Inc (SPRY)
$9.15
+0.11
(+1.22%)▲
Live
Insights on Ars Pharmaceuticals Inc
Decreasing Revenue
Revenue is down for the last 4 quarters, 1.31M → -30.0K (in $), with an average decrease of 182.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -7.16M → -10.29M (in $), with an average decrease of 43.6% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 47.7%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 303.7%
Performance
- $9.00$9.19$9.15
1.64%
Downside
Day's Volatility :2.07%
Upside
0.44%
- $2.55$11.27$9.15
72.13%
Downside
52 Weeks Volatility :77.37%
Upside
18.81%
Returns
| Period | Ars Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 4.51% | 0.0% |
6 Months | 73.51% | 0.0% |
1 Year | 30.26% | 0.0% |
3 Years | -68.64% | -22.6% |
Highlights
Market Capitalization | 860.4M |
Book Value | $2.32 |
Earnings Per Share (EPS) | -0.52 |
Wall Street Target Price | 19.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -619990.0% |
Return On Assets TTM | -15.54% |
Return On Equity TTM | -20.49% |
Revenue TTM | 10.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -97.8% |
Gross Profit TTM | 1.3M |
EBITDA | -61.9M |
Diluted Eps TTM | -0.52 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.65 |
EPS Estimate Next Year | -0.62 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | -0.13 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 107.65%
Technicals Summary
Sell
Neutral
Buy
Ars Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Ars Pharmaceuticals Inc | -4.34% | 73.51% | 30.26% | -68.64% | -63.84% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Ars Pharmaceuticals Inc | NA | NA | NA | -0.65 | -0.2 | -0.16 | NA | 2.32 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Ars Pharmaceuticals Inc | Buy | $860.4M | -63.84% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Institutional Holdings
RA Capital Management, LLC
9.76%Orbimed Advisors, LLC
9.54%Franklin Resources Inc
4.23%SR ONE CAPITAL MANAGEMENT, LP
4.14%Nantahala Capital Management, LLC
3.30%K2 PRINCIPAL FUND LP
3.15%
Company Information
silverback therapeutics is a biotechnology company that was founded in 2016. the company is based in seattle, wa and is funded by orbimed.
Organization | Ars Pharmaceuticals Inc |
Employees | 24 |
CEO | Mr. Richard Lowenthal M.B.A., M.S., MSMSEL |
Industry | Healthcare |
